USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
Hope, Unity (and Some Nerves) at the DNC
Outcry at Bank of America Over Dangerous Workloads
The Inside Story of Starbucks’s CEO Drama
At the DNC, Democrats Are Divided Over Gaza
The Economy: Trump vs. Harris
Is the Trump Campaign Going Off Track?
She Was Google’s First Landlord. And She Changed the Internet.
One Man’s Campaign Against DEI
China Is Finally Doing Something About the Fentanyl Crisis
Boeing's Long Flight Delay – in Space
Will Tracking Cocoa Beans Help Save the Rainforest?
$25 Billion to Zero: Bill Ackman’s Bungled IPO
Judge Rules ‘Google Is a Monopolist’
What the Stock Market Panic Says About the Economy
Who is Filing Thousands of Disability Lawsuits Against Businesses?
'Phony' and 'Weird.' Trump and Harris Size Each Other Up
The Historic U.S.-Russia Prisoner Swap
Alexa is in Millions of Homes and Amazon is Losing Billions
The Paris Olympics’ $1.5 Billion Poop Problem
The Slaves Sending You Scam Texts
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Minute Briefing
WSJ Tech News Briefing
Marketplace Tech